Leukaemia is a type of blood cancer that begins in the blood-forming tissues, primarily the bone marrow. It causes the production of abnormal blood cells, most commonly abnormal white blood cells, which can interfere with the normal production and function of healthy blood cells.
Leukaemia is not one single disease. It includes several different types, each with its own biological characteristics, rate of progression and treatment approach.
Bone marrow is the soft tissue found inside many bones. It is responsible for producing the blood cells that the body needs to carry oxygen, fight infections and control bleeding.
Red blood cells carry oxygen from the lungs to tissues throughout the body. A reduction in healthy red blood cells can lead to anaemia and symptoms such as tiredness and weakness.
White blood cells are part of the immune system and help the body respond to infections. Abnormal white blood cells in leukaemia may not function normally.
Platelets help blood clot and control bleeding. Reduced platelet production can result in easy bruising or bleeding.
Blood cells normally develop from blood-forming stem cells in the bone marrow. Genetic changes can cause some cells to develop and multiply abnormally.
In leukaemia, abnormal cells can accumulate in the bone marrow and blood. Depending on the type of leukaemia, these cells may multiply rapidly or more slowly.
As abnormal cells increase, they can interfere with the production of normal blood cells.
The symptoms and blood-count changes associated with leukaemia depend on which blood cell lines are affected and how extensively the abnormal cells have accumulated.
Low red blood cell levels can cause anaemia, which may result in tiredness, weakness, dizziness or breathlessness.
Abnormal white blood cells may not provide normal immune protection, potentially increasing the risk of infections.
A low platelet count can affect normal clotting and may lead to easy bruising, nosebleeds or other bleeding.
Leukaemia is broadly classified according to how quickly the disease progresses and the type of blood-forming cell involved. Understanding this classification is important because different types require different treatment strategies.
Acute leukaemias generally progress rapidly and involve immature blood-forming cells called blasts. They usually require prompt medical evaluation and treatment.
Chronic leukaemias generally develop more slowly and involve more mature blood cells. Some patients may have few symptoms when the disease is first detected.
The four major types are classified according to whether the abnormal cells arise from the myeloid or lymphoid blood-forming lineage and whether the disease is acute or chronic.
AML develops from myeloid blood-forming cells and generally progresses rapidly. Treatment often requires prompt specialist evaluation.
ALL develops from immature lymphoid cells. It can occur in both children and adults, with treatment depending on the patient's age and disease characteristics.
CML develops from the myeloid blood-forming lineage and is commonly associated with a specific genetic abnormality that can guide targeted treatment.
CLL affects a type of lymphocyte and generally progresses more slowly than acute leukaemias. Some patients may initially be monitored rather than treated immediately.
Important: Leukaemia is a complex group of diseases. A high or low white blood cell count by itself does not establish a diagnosis of leukaemia. Diagnosis requires appropriate blood tests and, when indicated, specialised haematological investigations.
If you have persistent abnormal blood counts, symptoms concerning for a blood disorder or a confirmed leukaemia diagnosis, a specialist oncology and haematology consultation can help determine the appropriate next steps.
Book an Oncology ConsultationLeukaemia is classified according to the type of blood-forming cell affected and how quickly the disease generally develops. The four major types are acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL), chronic myeloid leukaemia (CML) and chronic lymphocytic leukaemia (CLL).
Identifying the exact type of leukaemia is essential because treatment, prognosis and monitoring can differ substantially between these conditions.
Leukaemia is broadly described using two important classifications: whether it is acute or chronic, and whether the abnormal cells belong to the myeloid or lymphoid lineage.
Acute leukaemias generally develop rapidly and involve immature blood-forming cells. Chronic leukaemias generally develop more slowly and involve more mature cells.
Myeloid and lymphoid refer to different blood-forming cell lineages in the bone marrow. Identifying the affected lineage helps determine the specific type of leukaemia.
AML is a cancer of the myeloid blood-forming lineage. It usually progresses quickly because abnormal immature cells, known as blasts, can accumulate in the bone marrow and blood.
ALL develops from immature lymphoid cells. It is the most common type of leukaemia in children, but it can also occur in adults.
CML is a myeloid blood cancer that is commonly associated with the Philadelphia chromosome and the BCR::ABL1 fusion gene. This molecular abnormality plays an important role in diagnosis and treatment.
CLL is a cancer involving abnormal mature lymphocytes. It generally progresses more slowly than acute leukaemias and may be discovered during routine blood testing.
| Type | Cell lineage | General pattern | Important treatment consideration |
|---|---|---|---|
| AML | Myeloid | Acute and generally fast-growing | Treatment is guided by disease subtype, genetics and patient factors |
| ALL | Lymphoid | Acute and generally fast-growing | Treatment varies according to B-cell/T-cell lineage, genetics and clinical factors |
| CML | Myeloid | Usually chronic and slower-growing | BCR::ABL1-targeted treatment is central for most patients |
| CLL | Lymphoid | Usually chronic and slower-growing | Some patients can initially be monitored without immediate treatment |
Myeloid and lymphoid cells develop along different pathways from blood-forming stem cells. This distinction is one of the foundations of leukaemia classification.
Myeloid cells give rise to several types of blood cells, including red blood cells, platelets and certain types of white blood cells.
Lymphoid cells develop into lymphocytes, including B cells and T cells, which play important roles in the immune system.
Two people with the same broad type of leukaemia may have different biological characteristics. Modern diagnosis therefore goes beyond simply identifying an abnormal blood count.
Specific genetic or chromosomal changes can help define the disease and may identify treatments that are more appropriate for a particular patient.
Molecular testing can identify alterations that influence prognosis, treatment selection and monitoring of treatment response.
The amount of abnormal disease present and how it affects normal blood production can influence treatment decisions.
Age, overall health, previous treatment and other medical conditions are considered when developing an individualised treatment plan.
Important: The classification of leukaemia cannot be established from symptoms alone. Blood tests, bone marrow examination, flow cytometry and genetic or molecular investigations may be needed to determine the exact diagnosis and guide treatment.
Leukaemia can affect the normal production of red blood cells, white blood cells and platelets. As a result, symptoms may include persistent tiredness, frequent infections, fever, unusual bleeding or bruising and other changes in general health.
Symptoms can vary considerably depending on the type of leukaemia, how quickly it is progressing and how much the normal blood-cell production has been affected.
Some symptoms may develop gradually, while acute leukaemias can cause noticeable symptoms over a relatively short period.
Reduced red blood cell production can cause anaemia. This may lead to persistent tiredness, weakness, reduced stamina or a feeling of low energy even after adequate rest.
Abnormal or inadequate functioning white blood cells can reduce the body's ability to fight infections. Fever may occur with or without other symptoms of infection.
Repeated or persistent infections may occur when abnormal blood cells interfere with normal immune function.
A reduced platelet count can make bruising occur more easily, sometimes without an obvious injury.
Low platelet levels can contribute to nosebleeds, bleeding from the gums, unusually heavy menstrual bleeding or prolonged bleeding after minor injuries.
Unintentional weight loss can occur with some blood cancers, particularly when accompanied by other persistent symptoms.
Some people with blood cancers experience significant night sweating, particularly when it occurs repeatedly without an obvious environmental cause.
Abnormal blood-cell accumulation in the bone marrow can sometimes cause bone or joint discomfort.
Enlarged lymph nodes, particularly in the neck, armpit or groin, can occur with some forms of leukaemia.
Many symptoms of leukaemia are related to the way abnormal cells affect the bone marrow and reduce the production of healthy blood cells.
Fewer healthy red blood cells means less oxygen can be carried to tissues, contributing to tiredness, weakness and breathlessness.
Even when the total white blood cell count is high, the cells may be abnormal and unable to provide normal immune protection.
Reduced platelet production can interfere with normal blood clotting and lead to bruising or bleeding.
Acute leukaemias can progress rapidly. Symptoms may become noticeable over a relatively short period as abnormal cells interfere with normal blood-cell production.
Chronic leukaemias may progress more gradually. Some people have few symptoms initially and may discover the condition after a routine blood test.
Most of the symptoms associated with leukaemia can also occur because of many other conditions. Having one of these symptoms does not mean that a person has leukaemia.
However, persistent, unexplained or repeatedly occurring symptoms—particularly unusual bleeding or bruising, recurrent infections, persistent fever, significant fatigue or unexplained weight loss—should be discussed with a qualified doctor.
Ongoing tiredness accompanied by pale skin, weakness or breathlessness may warrant a blood count to assess for anaemia and other abnormalities.
New unexplained bruises combined with recurrent nosebleeds, gum bleeding or other unusual bleeding should be medically evaluated.
Repeated infections or unexplained persistent fever can have many causes but may require investigation of the immune and blood systems.
Enlarged lymph nodes accompanied by persistent fever, night sweats, weight loss or fatigue may require further assessment.
Persistent bone or joint pain together with an unexplained abnormal blood count should be assessed by a doctor.
Unexpected changes in haemoglobin, white blood cells or platelets may require additional blood tests and, when indicated, specialist haematological evaluation.
Diagnosing leukaemia involves more than identifying an abnormal blood count. Doctors use blood tests, examination of blood cells, bone marrow studies and specialised laboratory tests to determine whether leukaemia is present and, if so, identify its specific type and biological characteristics.
A precise diagnosis is important because treatment differs significantly between AML, ALL, CML, CLL and their individual subtypes.
The exact tests required depend on the symptoms, blood-test findings and suspected type of leukaemia.
Medical history, symptoms and physical examination help identify possible blood or systemic disorders.
A complete blood count and peripheral blood examination can identify abnormalities requiring further investigation.
Bone marrow examination may be needed to confirm the diagnosis and determine the type of leukaemia.
Genetic, cytogenetic and molecular tests can provide important information for classification and treatment planning.
A complete blood count is often one of the first investigations performed when a blood disorder is suspected. It measures several components of the blood and can reveal abnormalities that require additional testing.
A low haemoglobin level can indicate anaemia, although anaemia has many possible causes and does not by itself diagnose leukaemia.
The white blood cell count may be unusually high, low or otherwise abnormal depending on the type and stage of disease.
A reduced platelet count may occur when abnormal cells interfere with normal blood-cell production in the bone marrow.
A peripheral blood smear involves examining a sample of blood under a microscope. A trained laboratory professional can assess the appearance, number and maturity of blood cells.
The presence of abnormal or immature blood cells can provide important clues about a possible blood disorder and help determine which additional investigations are required.
Because leukaemia originates in blood-forming tissues, examination of the bone marrow is an important part of diagnosis for many patients.
A bone marrow aspiration collects a small sample of liquid marrow, while a biopsy obtains a small core of bone marrow tissue. These samples can be examined to determine the number, appearance and characteristics of blood-forming cells.
Flow cytometry analyses cells based on specific markers found on their surface or inside the cells. This helps doctors determine which blood-cell lineage the abnormal cells belong to.
Immunophenotyping can help distinguish between different leukaemia subtypes and can provide information that is important for treatment planning.
Some leukaemias are associated with characteristic chromosome changes. Cytogenetic testing can identify these abnormalities and contribute to disease classification.
Tests such as karyotyping can examine chromosomes for larger structural or numerical changes.
FISH can identify selected genetic or chromosomal abnormalities using targeted probes and may provide results for specific abnormalities more quickly than conventional chromosome analysis.
Modern leukaemia diagnosis increasingly uses molecular testing to identify genetic changes within abnormal cells. These findings can influence disease classification, prognosis and treatment selection.
Leukaemia is biologically diverse. Identifying relevant molecular changes allows treatment decisions to be based not only on the appearance of the disease but also on its specific biological characteristics.
Blood chemistry tests may be used to assess kidney, liver and other organ functions before and during treatment.
Depending on the planned treatment, screening for certain infections may be recommended before therapy begins.
Imaging tests may be considered when there is a clinical reason to assess lymph nodes, organs or other areas of concern.
Further investigations may be selected according to the suspected leukaemia subtype, symptoms and individual clinical circumstances.
No single test provides every piece of information required to classify leukaemia. Doctors combine clinical findings with blood, bone marrow, immunophenotyping and genetic information.
The goal is not simply to confirm that abnormal cells are present. The diagnostic process aims to determine the exact disease subtype, understand its biological characteristics, assess relevant risk factors and identify information that can guide treatment.
Important: An abnormal CBC or white blood cell count does not automatically mean that a person has leukaemia. Infections, medications, nutritional deficiencies, inflammatory conditions and other disorders can also alter blood counts. A qualified doctor should interpret test results in the context of the individual's symptoms and medical history.
Leukaemia treatment depends on the exact type of disease, its genetic and molecular characteristics, the extent of disease, the patient's age and overall health, and whether the disease is newly diagnosed or has returned after treatment.
Treatment may involve chemotherapy, targeted therapy, immunotherapy, stem cell transplantation and supportive care. For some patients, active monitoring may be appropriate, particularly in selected chronic leukaemias where immediate treatment is not required.
Modern leukaemia care uses different treatment approaches depending on the biological characteristics of the disease.
Chemotherapy uses medicines that target rapidly dividing cancer cells. It remains an important part of treatment for several types of acute leukaemia.
Targeted medicines are designed to act on specific molecular abnormalities or pathways involved in the growth and survival of leukaemia cells.
Immunotherapy uses the body's immune system or immune-targeting medicines to recognise and attack abnormal blood cells.
Genetic and molecular information can help identify disease characteristics that influence treatment selection and monitoring.
There is no single treatment plan that applies to every person with leukaemia. The approach is selected according to the specific disease subtype and its biological characteristics.
Treatment may include intensive or lower-intensity systemic therapy, targeted medicines and, in selected patients, stem cell transplantation.
Treatment generally involves multi-phase systemic therapy, with treatment selection influenced by disease subtype and molecular findings.
Targeted tyrosine kinase inhibitors are central to treatment for most patients with BCR::ABL1-positive CML.
Some patients can initially be observed. When treatment is required, targeted medicines and other systemic therapies may be considered.
Chemotherapy medicines interfere with the growth and division of cancer cells. Depending on the type of leukaemia, treatment may be administered intravenously, orally or through other routes as part of a structured treatment protocol.
Acute leukaemia treatment may be divided into phases designed to achieve remission, deepen the response and reduce the risk of the disease returning.
Targeted therapy is an important part of modern blood-cancer treatment. These medicines are selected according to specific molecular features of the disease when an appropriate target is present.
In CML, the BCR::ABL1 fusion protein is a key driver of the disease. Tyrosine kinase inhibitors can specifically inhibit this pathway and are a major component of CML treatment.
Certain genetic alterations found in other leukaemias may also provide targets for specific medicines. The appropriate therapy depends on the individual molecular profile.
Some leukaemias can be treated using medicines that recognise specific proteins on abnormal cells or otherwise help the immune system attack leukaemia cells.
These medicines are designed to recognise specific markers on abnormal blood cells and can be used in selected leukaemia subtypes.
Advanced cellular treatments, including CAR-T cell therapy, may be considered for selected patients with particular relapsed or refractory blood cancers when clinically appropriate.
Precision oncology in leukaemia involves using diagnostic, cytogenetic and molecular information to understand the biology of an individual's disease and identify appropriate treatment options.
Supportive care is an important part of leukaemia treatment. It helps manage complications caused by the disease or its treatment and supports the patient throughout therapy.
Red blood cell or platelet transfusions may be required in selected patients depending on blood counts and clinical symptoms.
Patients receiving intensive treatment may require careful monitoring and prompt management of infections.
Nausea, fatigue, changes in blood counts and other treatment effects can be managed with appropriate supportive measures.
Appropriate nutrition and hydration can support general wellbeing during treatment, based on individual medical needs.
Regular blood tests help the treatment team assess blood-cell recovery and identify complications early.
Emotional and psychological support can be an important part of comprehensive cancer care for patients and families.
Treatment decisions are made after considering the complete clinical and laboratory picture rather than relying on a single test or symptom.
AML, ALL, CML and CLL require different treatment approaches, and further subtyping may be necessary.
Specific genetic changes can influence treatment selection and help identify targeted treatment options.
Age, general health, organ function and other medical conditions are considered when choosing an appropriate treatment intensity.
Blood, bone marrow and molecular assessments may be used to evaluate response and guide subsequent treatment decisions.
A specialist consultation can help review the diagnosis, pathology and molecular findings and determine which treatment approaches may be appropriate for the individual patient.
Book an Oncology ConsultationStem cell transplantation, also known as haematopoietic stem cell transplantation, can be an important treatment option for selected patients with leukaemia. It involves replacing diseased or damaged blood-forming cells with healthy haematopoietic stem cells.
Transplantation is not required for every person with leukaemia. The decision depends on the type and risk characteristics of the disease, response to initial treatment, likelihood of relapse, overall health and availability of a suitable donor when an allogeneic transplant is being considered.
Transplantation is generally considered when the expected benefit of replacing the diseased blood-forming system outweighs the risks associated with the procedure.
Some patients with high-risk or biologically aggressive leukaemia may be considered for transplantation after achieving an appropriate treatment response.
A transplant may be considered for selected patients whose disease has returned after previous treatment.
In some situations, transplantation may form part of a treatment strategy when the disease has not responded adequately to initial therapy.
Genetic findings, response to treatment and measurable residual disease can influence whether transplantation should be considered.
In an allogeneic transplant, stem cells are obtained from another person whose tissue type is sufficiently compatible with the patient.
In an autologous transplant, the patient's own stem cells are collected and stored before high-dose treatment and then returned to the patient.
Its role varies considerably by disease and is not the standard transplant approach for every type of leukaemia.
For an allogeneic transplant, doctors assess human leukocyte antigen (HLA) compatibility between the patient and potential donors.
A brother or sister may have a suitable HLA match, although compatibility cannot be assumed based only on being related.
If a suitable family donor is unavailable, an unrelated donor from an appropriate donor registry may be considered.
Advances in transplantation have made alternative donor approaches possible for selected patients when a conventional matched donor is unavailable.
The transplant process involves several carefully planned stages. The exact protocol depends on the patient's disease and treatment strategy.
The patient's disease status, organ function and overall health are assessed.
HLA testing is performed when an allogeneic transplant is planned.
Chemotherapy, with or without radiation, prepares the body for transplantation.
Healthy stem cells are infused through an intravenous line.
The new stem cells begin producing blood cells while the patient is closely monitored.
Higher-intensity conditioning uses chemotherapy, sometimes combined with radiation, to destroy a substantial amount of existing bone marrow and cancer cells before stem cell infusion.
Lower-intensity approaches may be considered for selected patients who may not tolerate conventional high-intensity conditioning.
One important feature of an allogeneic transplant is the graft-versus-leukaemia effect. Donor immune cells may recognise and attack remaining leukaemia cells that were not eliminated by chemotherapy or other treatment.
Stem cell transplantation can provide substantial benefit for appropriately selected patients, but it is also an intensive treatment with potentially serious complications.
Blood counts can remain low during the early recovery period, increasing susceptibility to bacterial, viral and fungal infections.
In an allogeneic transplant, donor immune cells may attack healthy tissues. This is known as graft-versus-host disease and requires careful monitoring and treatment.
Anaemia, low platelet counts and low white blood cell counts can occur during the transplant and recovery period.
Conditioning and transplantation can affect organs such as the liver, kidneys, lungs or heart in some patients.
Transplant suitability must be assessed individually. The potential benefits, risks, alternative treatments and expected recovery should be discussed with the treating haematology or oncology team before making a treatment decision.
Treatment options for blood cancers continue to evolve. Selected patients with relapsed or refractory disease may be considered for advanced cellular or immune-based therapies depending on the exact diagnosis and treatment history.
CAR-T therapy modifies a patient's T cells so that they can recognise specific targets on cancer cells. It is used for selected blood cancers and may be considered in particular clinical situations.
New targeted agents, antibody-based therapies and cellular approaches continue to be studied for different forms of leukaemia, particularly in relapsed or treatment-resistant disease.
Blood counts are monitored closely to determine when the transplanted stem cells begin producing healthy blood cells.
Infection precautions, medicines and vaccinations may form part of the longer-term recovery plan.
Blood, bone marrow and molecular tests may be used to monitor the response and detect measurable residual disease when appropriate.
Regular follow-up helps identify late complications, manage treatment effects and monitor ongoing disease control.
A specialist consultation can help review the leukaemia subtype, treatment response and molecular findings and determine whether transplantation or other advanced treatment approaches may be appropriate.
Book an Oncology ConsultationStem cell transplantation, also known as haematopoietic stem cell transplantation, can be an important treatment option for selected patients with leukaemia. It involves replacing diseased or damaged blood-forming cells with healthy haematopoietic stem cells.
Transplantation is not required for every person with leukaemia. The decision depends on the type and risk characteristics of the disease, response to initial treatment, likelihood of relapse, overall health and availability of a suitable donor when an allogeneic transplant is being considered.
Transplantation is generally considered when the expected benefit of replacing the diseased blood-forming system outweighs the risks associated with the procedure.
Some patients with high-risk or biologically aggressive leukaemia may be considered for transplantation after achieving an appropriate treatment response.
A transplant may be considered for selected patients whose disease has returned after previous treatment.
In some situations, transplantation may form part of a treatment strategy when the disease has not responded adequately to initial therapy.
Genetic findings, response to treatment and measurable residual disease can influence whether transplantation should be considered.
In an allogeneic transplant, stem cells are obtained from another person whose tissue type is sufficiently compatible with the patient.
In an autologous transplant, the patient's own stem cells are collected and stored before high-dose treatment and then returned to the patient.
Its role varies considerably by disease and is not the standard transplant approach for every type of leukaemia.
For an allogeneic transplant, doctors assess human leukocyte antigen (HLA) compatibility between the patient and potential donors.
A brother or sister may have a suitable HLA match, although compatibility cannot be assumed based only on being related.
If a suitable family donor is unavailable, an unrelated donor from an appropriate donor registry may be considered.
Advances in transplantation have made alternative donor approaches possible for selected patients when a conventional matched donor is unavailable.
The transplant process involves several carefully planned stages. The exact protocol depends on the patient's disease and treatment strategy.
The patient's disease status, organ function and overall health are assessed.
HLA testing is performed when an allogeneic transplant is planned.
Chemotherapy, with or without radiation, prepares the body for transplantation.
Healthy stem cells are infused through an intravenous line.
The new stem cells begin producing blood cells while the patient is closely monitored.
Higher-intensity conditioning uses chemotherapy, sometimes combined with radiation, to destroy a substantial amount of existing bone marrow and cancer cells before stem cell infusion.
Lower-intensity approaches may be considered for selected patients who may not tolerate conventional high-intensity conditioning.
One important feature of an allogeneic transplant is the graft-versus-leukaemia effect. Donor immune cells may recognise and attack remaining leukaemia cells that were not eliminated by chemotherapy or other treatment.
Stem cell transplantation can provide substantial benefit for appropriately selected patients, but it is also an intensive treatment with potentially serious complications.
Blood counts can remain low during the early recovery period, increasing susceptibility to bacterial, viral and fungal infections.
In an allogeneic transplant, donor immune cells may attack healthy tissues. This is known as graft-versus-host disease and requires careful monitoring and treatment.
Anaemia, low platelet counts and low white blood cell counts can occur during the transplant and recovery period.
Conditioning and transplantation can affect organs such as the liver, kidneys, lungs or heart in some patients.
Transplant suitability must be assessed individually. The potential benefits, risks, alternative treatments and expected recovery should be discussed with the treating haematology or oncology team before making a treatment decision.
Treatment options for blood cancers continue to evolve. Selected patients with relapsed or refractory disease may be considered for advanced cellular or immune-based therapies depending on the exact diagnosis and treatment history.
CAR-T therapy modifies a patient's T cells so that they can recognise specific targets on cancer cells. It is used for selected blood cancers and may be considered in particular clinical situations.
New targeted agents, antibody-based therapies and cellular approaches continue to be studied for different forms of leukaemia, particularly in relapsed or treatment-resistant disease.
Blood counts are monitored closely to determine when the transplanted stem cells begin producing healthy blood cells.
Infection precautions, medicines and vaccinations may form part of the longer-term recovery plan.
Blood, bone marrow and molecular tests may be used to monitor the response and detect measurable residual disease when appropriate.
Regular follow-up helps identify late complications, manage treatment effects and monitor ongoing disease control.
A specialist consultation can help review the leukaemia subtype, treatment response and molecular findings and determine whether transplantation or other advanced treatment approaches may be appropriate.
Book an Oncology ConsultationAccurate diagnosis and regular monitoring are essential parts of leukaemia care. Blood tests, bone marrow examination, immunophenotyping, cytogenetic studies and molecular testing may be used to identify the exact type of leukaemia and assess how well treatment is working.
Monitoring does not end after treatment begins. Ongoing assessment helps the treating team determine whether the disease is responding, whether treatment needs to be adjusted and whether there is evidence of residual or returning disease.
Diagnosis usually involves combining clinical findings with laboratory and specialised blood or bone marrow tests.
A complete blood count can identify abnormalities in white blood cells, red blood cells and platelets and may provide the first indication that further investigation is required.
A blood smear may allow a specialist to examine the appearance of blood cells and identify abnormal or immature cells.
Bone marrow aspiration and biopsy can provide important information about abnormal blood-forming cells and help establish the diagnosis and disease subtype.
Flow cytometry can examine proteins expressed by abnormal cells and help distinguish different types and subtypes of leukaemia.
Genetic and molecular tests can provide information about the biological characteristics of leukaemia and may influence prognosis, treatment selection and response monitoring.
Examines chromosomes in leukaemia cells and may identify characteristic abnormalities.
Fluorescence in situ hybridisation can detect specific chromosomal or genetic changes.
Polymerase chain reaction can detect specific molecular abnormalities and is useful for monitoring selected diseases.
NGS panels can identify multiple genetic alterations in selected patients and clinical situations.
Measurable residual disease, often called MRD, refers to a very small number of abnormal cells that may remain after treatment even when routine examination suggests that the patient is in remission.
In appropriate types of leukaemia, MRD testing can provide a more sensitive assessment of treatment response than routine blood counts alone.
| Assessment | What It Helps Assess | When It May Be Used |
|---|---|---|
| Blood Counts | Recovery of normal blood cells and changes in abnormal counts. | Throughout treatment and follow-up. |
| Bone Marrow Examination | Presence or absence of abnormal cells and overall marrow response. | At diagnosis and at selected treatment milestones. |
| Flow Cytometry | Identification of abnormal cell populations and, in appropriate settings, MRD. | During response assessment and follow-up. |
| Molecular Testing | Detection or measurement of specific molecular abnormalities. | When the disease has a suitable molecular marker. |
Complete remission generally means that the disease meets defined clinical and laboratory criteria for remission. However, remission does not necessarily mean that every abnormal cell has been eliminated.
Sensitive tests such as MRD assessment may provide additional information about the depth of response in leukaemias where these tests are validated and clinically useful.
Regular follow-up is important because leukaemia can return in some patients after an initial response. The monitoring plan depends on the type of leukaemia and the treatment received.
Periodic blood counts can identify changes that may require further evaluation.
In diseases with a measurable molecular marker, molecular testing can be particularly useful for detecting changes before they become apparent through routine assessment.
If blood tests or clinical findings raise concern about recurrence, a bone marrow examination may be recommended.
Symptoms, physical examination, treatment history and test results are considered together rather than in isolation.
Follow-up continues after active treatment has finished. The frequency and type of monitoring depend on the specific diagnosis, previous treatment and individual risk.
Scheduled consultations help assess recovery and ongoing disease control.
Blood and other tests are performed according to the disease and treatment history.
Some patients require monitoring for longer-term effects of cancer treatment.
Nutrition, emotional wellbeing and general health remain part of comprehensive follow-up care.
Patients undergoing or recovering from leukaemia treatment should follow the specific instructions provided by their medical team. Fever, signs of infection, unusual bleeding, severe weakness, breathing difficulty or other sudden changes may require prompt medical assessment.
Reviewing the diagnosis, molecular findings and treatment response together can help the oncology team develop an appropriate individualised treatment and monitoring plan.
Book an Oncology ConsultationA diagnosis of leukaemia does not have the same outlook for every patient. Leukaemia includes several different diseases, and treatment response and long-term outcomes can vary considerably between individuals.
Advances in diagnosis, targeted therapy, immunotherapy, stem cell transplantation and supportive care have significantly expanded treatment options for many patients. Prognosis should therefore be discussed in the context of the exact leukaemia subtype, molecular findings and individual response to treatment.
Doctors consider multiple clinical and biological factors when assessing prognosis and planning treatment.
AML, ALL, CML and CLL have different biological characteristics, treatment strategies and expected outcomes.
Certain chromosomal and molecular abnormalities can influence disease behaviour and treatment response.
Age, fitness, organ function and other medical conditions may influence treatment choices and tolerance.
The depth and speed of response to initial treatment can provide important information about disease behaviour.
Where validated, MRD assessment can provide additional information about the depth of remission and risk of relapse.
Previous treatment and whether the disease has returned can influence subsequent treatment strategies.
Healthy daily habits can support general wellbeing during cancer treatment and recovery. However, lifestyle measures should complement—not replace—medical treatment.
A varied, nutritious diet can help support energy and recovery. Patients undergoing intensive treatment may need individualised dietary advice.
Gentle activity may help maintain strength and wellbeing when medically appropriate. Activity levels should be adjusted according to blood counts and treatment status.
Fatigue is common during cancer treatment. Regular rest and appropriate sleep can support recovery.
Patients with low blood counts may need additional precautions to reduce exposure to infections as advised by their medical team.
Some leukaemia treatments can temporarily weaken the immune system. Food safety becomes particularly important when white blood cell counts are low or when advised by the treating team.
Anxiety, uncertainty, sleep difficulties and emotional stress can occur after a leukaemia diagnosis. Patients and families may benefit from speaking with a counsellor, psychologist, support group or member of the cancer care team.
Caregivers may also experience emotional and practical challenges. Clear communication with the medical team can help families understand treatment plans, follow-up and warning signs.
Patients receiving leukaemia treatment should follow the emergency instructions provided by their treating team. Certain symptoms should not be ignored.
Fever, chills, persistent cough, breathlessness or other signs of infection may require urgent medical assessment, especially when white blood cell counts are low.
Significant bleeding, unexplained bruising, blood in urine or stool or persistent nosebleeds should be reported promptly.
Sudden or severe weakness, dizziness or difficulty performing normal activities may require medical evaluation.
New or worsening difficulty breathing, chest discomfort or significant shortness of breath should receive prompt medical attention.
Some forms of leukaemia can be cured, while others can often be controlled for many years with appropriate treatment. Outcomes depend on the exact type, molecular characteristics, response to treatment and individual patient factors.
There is no single best treatment for all leukaemias. Treatment depends on the specific subtype, genetic findings, disease risk, age, overall health and treatment response.
No. Treatment varies by leukaemia type. Some patients may receive targeted medicines, immunotherapy or other approaches, while selected patients with certain chronic leukaemias may initially be monitored without immediate treatment.
No. Stem cell transplantation is considered only when the potential benefits justify the risks for an individual patient. Disease risk, treatment response, relapse risk and overall health are among the factors considered.
MRD stands for measurable residual disease. It refers to a very small amount of abnormal disease that may remain after treatment. In suitable types of leukaemia, sensitive tests can detect MRD and help assess the depth of treatment response.
Relapse can occur in some patients, although the risk varies considerably according to the type of leukaemia and individual disease characteristics. Regular follow-up helps detect changes early and allows treatment to be considered when necessary.
Treatment duration varies widely. Some acute leukaemias involve several phases of therapy over months or longer, while certain chronic leukaemias may require ongoing targeted treatment and monitoring.
No. There is no diet proven to cure leukaemia. Good nutrition can support general health and recovery, but it should not replace evidence-based cancer treatment.
Anyone with suspected or confirmed leukaemia should be evaluated by an appropriate haematology or oncology specialist. Specialist review is particularly important when interpreting bone marrow, flow cytometry, cytogenetic or molecular test results and planning treatment.
This information is intended for general educational purposes only and should not be considered a substitute for professional medical advice, diagnosis or treatment. Leukaemia treatment is highly individualised. Treatment decisions should be made in consultation with a qualified haematologist or oncologist after reviewing the patient's medical history, investigations, pathology and molecular findings.
If you or a family member has been diagnosed with leukaemia, specialist evaluation can help clarify the diagnosis, understand available treatment options and develop an individualised care plan.
Book an Oncology Consultation
Precision Oncology Clinic, the best Cancer Clinic in Bangalore, located in Vijayanagar. Book appointment!
©2024. All Rights Reserved. Precision Oncology Clinic
By HAAPS
Book Appointment